• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Aptose Bioscns (NQ: APTO )

    0.5084 +0.0242 (+5.00%)
    Streaming Delayed Price Updated: 10:11 AM EDT, Aug 16, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Aptose Bioscns

    < Previous 1 2 3 4 5 Next >
    Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Expert Ratings for Aptose Biosciences
    Via Benzinga
    Analyst Expectations for Aptose Biosciences's Future
    Via Benzinga
    Canaccord Genuity Maintains Buy Rating for Aptose Biosciences: Here's What You Need To Know
    Via Benzinga
    Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference
    Company to Hold Clinical Update Webcast; Details Forthcoming 
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose to Present at the Cantor Global Healthcare Conference
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical
    — TUS/VEN doublet continues safe and effective in AML patients who failed prior venetoclax — 
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Preview: Aptose Biosciences's Earnings
    Via Benzinga
    Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    RBC Capital Maintains Outperform Rating for Aptose Biosciences: Here's What You Need To Know
    Via Benzinga
    Aptose Reports Results for the Second Quarter 2023
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Stocks That Hit 52-Week Lows On Wednesday
      Wednesday saw 59 companies set new 52-week lows. 
    Via Benzinga
    Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Presents Highlights from Clinical Update
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Biosciences Provides Update on Reverse Stock Split
    Common Shares to begin trading on adjusted basis June 6 
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023
    EHA Abstract on Tuspetinib and Venetoclax Recently Published 
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Enters into $25 Million Committed Equity Facility
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Why Inovio Pharmaceuticals Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
    Gainers Minerva Surgical, Inc. (NASDAQ: UTRS) shares rose 202.3% to $0.5499 in pre-market trading. Minerva Surgical was granted U.S. Patent #11653972 for "Medical Systems And Methods (For Resecting And... 
    Via Benzinga
    Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    3 Stocks With 1,000% Upside Potential
    If you're an investor comfortable with speculative bets, analysts are price targeting these stocks with 1000% upside. 
    Via InvestorPlace
    Aptose Reports Results for the First Quarter 2023
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose to Participate in RBC Capital Markets 2023 Global Healthcare Conference
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose to Report First Quarter 2023 Financial Results and Hold Conference Call on Monday, May 8, 2023
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Biosciences to Participate in Cantor’s The Future of Oncology Virtual Symposium
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Reports Results for the Fourth Quarter and Full Year 2022
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Earnings Scheduled For March 23, 2023
    Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter. 
    Via Benzinga
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.